Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. decreased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 18.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 68,998 shares of the company’s stock after selling 15,966 shares during the quarter. Victory Capital Management Inc.’s holdings in Harmony Biosciences were worth $2,760,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Pacer Advisors Inc. raised its stake in Harmony Biosciences by 0.6% during the second quarter. Pacer Advisors Inc. now owns 2,509,609 shares of the company’s stock worth $75,715,000 after acquiring an additional 14,695 shares during the period. Dimensional Fund Advisors LP raised its stake in Harmony Biosciences by 13.3% during the second quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock worth $28,871,000 after acquiring an additional 112,197 shares during the period. American Century Companies Inc. raised its stake in Harmony Biosciences by 53.7% during the second quarter. American Century Companies Inc. now owns 681,536 shares of the company’s stock worth $20,562,000 after acquiring an additional 238,140 shares during the period. Renaissance Technologies LLC raised its stake in Harmony Biosciences by 56.7% during the second quarter. Renaissance Technologies LLC now owns 595,800 shares of the company’s stock worth $17,975,000 after acquiring an additional 215,700 shares during the period. Finally, LSV Asset Management raised its stake in Harmony Biosciences by 72.5% during the second quarter. LSV Asset Management now owns 578,246 shares of the company’s stock worth $17,446,000 after acquiring an additional 243,100 shares during the period. Institutional investors and hedge funds own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Raymond James restated an “outperform” rating and issued a $40.00 price target on shares of Harmony Biosciences in a research note on Thursday, October 10th. Cantor Fitzgerald raised their price target on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Needham & Company LLC restated a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a research note on Tuesday, October 29th. Mizuho raised their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday, October 10th. Finally, UBS Group assumed coverage on shares of Harmony Biosciences in a research note on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price target on the stock. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $47.00.

Insider Buying and Selling

In related news, insider Jeffrey Dierks sold 21,496 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 30.80% of the stock is currently owned by insiders.

Harmony Biosciences Trading Up 2.5 %

Harmony Biosciences stock opened at $34.07 on Friday. The firm has a 50 day simple moving average of $35.53 and a 200-day simple moving average of $33.55. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The stock has a market capitalization of $1.94 billion, a PE ratio of 16.15, a price-to-earnings-growth ratio of 0.62 and a beta of 0.77. Harmony Biosciences Holdings, Inc. has a 12-month low of $28.14 and a 12-month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.15. The business had revenue of $186.00 million during the quarter, compared to analysts’ expectations of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business’s revenue was up 16.0% on a year-over-year basis. During the same period last year, the firm posted $0.63 earnings per share. As a group, equities research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.